Drugs / [89Zr]Zr-DFO-emapalumab
[89Zr]Zr-DFO-emapalumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06439914 | Mar 2026 → Jun 2028 expected | non-small cell lung carcinoma | Nerissa T. Viola | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [89Zr]Zr-DFO-emapalumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06439914 ↗ |
| Modality | Diagnostic / imaging agent | “use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent” NCT06439914 ↗ |